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TITLE OF THE ABSTRACT : A prospective study of the demographic profile and clinical 
outcomes of newly diagnosed patients with acute myeloid leukemia at our centre. 
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DEGREE AND SUBJECT  : DM (Clinical Haematology) 
 
NAME OF THE GUIDE  : Vikram Mathews 
 
AIM / OBJECTIVES:  
 
1. Study the incidence and demographic profile of newly diagnosed adult acute myeloid 
leukemia at our centre 
 
2. Evaluate treatment and clinical outcome of the patients treated at our center.  
 
 
MATERIAL AND METHODS:  
Newly diagnosed patients at the department of clinical haematology were administered a 
questionnaire at presentation. Patients proceeding with therapy were prospectively followed up 
and outcomes noted. Patients who did not proceed with treatment were re-interviewed 
subsequently to confirm status and treatment. Descriptive statistics were calculated for all 
variables. Differences in proportions were assessed using the χ2 or Fisher exact statistic. 
Differences in means were tested using a Mann-Whitney-U test or t-test as appropriate. The 
probability of survival was estimated with product-limit method of Kaplan and Meier for overall 
survival and event-free survival and compared by the log-rank test. 
 
RESULTS:   
There were 318 newly diagnosed patients were evaluable for the study. The median age at 
presentation was 40(1-79) years. 95 (29.9%) patients proceed to treatment.148 (69.2%) patients 
had AML with intermediate cytogenetic risk. 174(81%) patients did not proceed with treatment 
due to inability to finance the costs of therapy. CR/CRi was achieved in 13(59.1%), 37(58.7%) 
and 1(10.0%) patient in the paediatric, adult and elderly group respectively; (P=0.005). The most 
common organism in the blood cultures with isolates were [GNB] gram negative bacilli 
[37(39%)]. The one year overall survival in those treated, was 58.7% ± 6.0%  at a median follow 
up of 3 months. 
 
 
CONCLUSIONS: 
The median age of patients with AML noted in our study is three decades earlier than that 
reported in the literature. The inability to finance treatment costs and inability to accompany the 
patient for the duration of therapy are the main reasons in declining therapy identified in our 
study. Another major concern is the incidence of infections both bacterial and fungal, higher than 
reported in literature with invasive fungal disease is present in greater than 50% of individuals 
who die during induction. 
 
 
Key Words: Demographics, AML, Treatment. 
 
INTRODUCTION: 
Acute myeloid leukemia (AML) is a heterogeneous clonal disorder of haematopoietic progenitor 
cells unable to differentiate and respond to normal regulators of proliferation. The standard of 
care in treatment has remained induction chemotherapy with anthracycline and cytosine followed 
by consolidation. In adults with acute myeloid leukemia (AML), intensive chemotherapy 
achieves complete remission (CR) rates ranging from 50% to 80%. Despite these encouraging 
results, the majority of patients with the diagnoses who present at our centre do not receive 
conventional therapy. Recent progress into the biology of the disease has involved dose 
modifications within the current standards of care .These improvements though significant might 
not contribute into improving treatment outcomes in a resource restricted economy like ours 
where costs of therapy are unaffordable to the majority. In an earlier study from our centre it was 
recognized that only 20 % of patients with AML proceed to receive conventional therapy.  We 
need to identify factors which influence treatment decisions and outcomes in addition to dose 
modifications to be socially relevant.  
One of the clinical challenges lies in accurately predicting and prognosticating those who relapse 
and those who attain cure by better detection of Minimal Residual Disease (MRD).It is also 
recognized that treatment outcomes amongst similar patient groups differ. WT1 is a uniformly 
available disease marker that needs to be explored as a tool for MRD.  
An analysis of the epidemiology, clinical features and outcome of the disease would enable an 
understanding of the disease in our population. Such an analysis would also enable caregivers 
and treatment providers to plan and allocate therapeutic strategies to optimize treatment in our 
patients with Acute Myeloid Leukemia. 
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REVIEW OF LITERATURE 
 
Acute myeloid leukemia is a clonal hematopoietic disorder characterized by an impairment in 
self-renewal, differentiation and proliferation of the myeloid  stem cell compartment due to 
acquired somatic mutations(1).It is more common with advancing age; and, as the population 
ages, more cases of AML are expected (2-4). 
 
Currently AML is categorized based on the World Health Organization (WHO) classification 
into four major subgroups .The first group features recurrent genetic abnormalities of prognostic 
significance. The second group is characterized as AML with Myelodysplasia-related changes 
and the third group is classified as therapy-related myeloid neoplasms. The fourth is the group of   
AML not otherwise specified (NOS), the definition being based on morphological , cytochemical 
and immuno-phenotypic features, representing the earlier FAB classification(5).
 
 
It is recognised to evolve by a multistep mechanism involving the occurrence of two classes of 
mutations. One group (class I) comprises mutations that activate signal transduction pathways 
and thereby increase the proliferation or survival, or both, of hematopoietic progenitor cells. The 
other complementation group (class II) comprises mutations that affect transcription factors or 
components of the cell cycle machinery and cause impaired differentiation (6).Mutations in KIT, 
FLT3, and NRAS fall into the class I mutations. Class II Mutations are those involving  
mutations in the core binding factorβ, RUNX1,MLL, BAAL, Wilm’s tumor gene (WT-1), 
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CCAAT/enhancer-binding protein α (CEBPα), and Nucleophosmin 1 (NPM1)(7, 8). A new class 
(class III) of mutations involving IDH1, AXL etc. affecting epigenetic regulation is also being 
increasingly recognized(9). 
Acute Myeloid leukemia- Therapeutics 
Despite the ability to achieve complete remission rates of 50-80% following induction; the 
current five-year survival rates of patients under age 60 who receive intensive chemo -therapy 
for AML range from 30% to over 40%(10-16). 
With more information being available about the prognostic factors, molecular biology and 
molecular genetics of acute myeloid leukemia (AML) there has been an improved understanding 
leading to modifications in therapy.(17-20)However for the past 30 years, except for the 
increasing use of allogeneic bone marrow transplantation because of an ever-increasing unrelated 
donor pool and the use of reduced-intensity conditioning for older patients and those with co 
morbidities;treatment of AML has consisted of the combinations of anthracyclines with 
cytarabine (21, 22). 
Therapy consists of two phases: 
i. Induction-   The goal is to achieve a complete remission (CR), defined as bone marrow 
with less than 5% blasts, an absolute neutrophil count (ANC) greater than 1000/mm
3
, 
with a platelet count greater than 100 000/mm
3
(16). 
CR is the only response reported consistent with cure or at least an extension in survival(23). 
For the past three decades induction has essentially consisted of a combination of 
anthracycline with cytarabine. Traditionally the anthracycline used has been daunorubicin. 
Comparisons amongst various anthracyclines and dose modifications have been tried(24). 
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Several studies have compared alternatives to daunorubicin without convincingly 
establishing benefit. However, there are questions regarding the dose equivalence of 
daunorubicin, mitoxantrone and idarubicin. Improvements may show itself not only by the 
proportion of patients entering complete remission, but also in reducing relapse. The addition 
of a third drug has been tested with no convincing benefit mixed results for etoposide, 
mitoxantrone or thioguanine. Their benefits may cost more procedural mortality with failure 
to deliver post induction therapy (25-27). 
Dose escalation of daunorubicin has also been explored with a recent study claiming a 
potential new standard of care at a dose level of 90 mg/m
2
(28).A criticism of this study has 
been the outcomes of the control were lower than expected. A comparison of an 80mg/m
2
 
daunorubicin with idarubicin showed no difference suggesting that the traditional dose of 
daunorubicin may be suboptimal but equivalent to idarubicin at 12 mg/m
2
(29-31). Several 
attempts have been made to modify the dose and the duration of cytarabine but with no 
conclusive improvement in overall survival (OS). Cytarabine irrespective of daily dose of 
200 mg/m
2
 by continuous infusion , twice per day bolus, doubling to 400 mg/m
2
, extending 
to 10 days or escalating to a 3g/m
2
, has not made a major impact(32).Treatment with 
fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin though shown 
to reduce the relapse rate without improving CR is at the cost of more myelosuppression and 
ability to deliver post induction treatment(31). 
ii. Consolidation- The aim of the second phase of therapy is to prolong the complete 
remission. 
Various options for consolidation include: 
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a) Intensive non-myeloablative consolidative chemotherapy 
b) Autologous stem cell transplantation.  
c) Allogeneic stem cell transplantation.  
Intensive consolidation chemotherapy associated with the lowest treatment related mortality 
(TRM); has the highest risk of disease relapse in comparison to an allogeneic SCT, which in 
contrast is associated with the lowest risk of disease recurrence, but with the highest risk of 
TRM. (31)An autologous SCT has an intermediate risk of TRM and relapse risk in two the other 
two options (31, 33-35). 
The option for the type consolidation therapy is strongly influenced by the cytogenetic risk 
group. The good, intermediate and adverse groups have a risk of  25%, 50%, and ≥ 70% of 
relapse and a corresponding 4-year probability of survival of ≥ 70%, 40% - 50%, and ≤ 20%(36). 
Parameters, such as age, response to induction chemotherapy, white blood cell count at diagnosis 
and type of consolidation therapy; alter these predicted outcomes (18-20). 
In view of the TRM of 15% to 30%; an allogeneic SCT is not considered in the good-risk group, 
when repetitive cycles of high-dose non-myeloablative consolidation chemotherapy can achieve 
long-term DFS greater than 70% with a less than 5% TRM (11, 37). 
In contrast the choice would be to proceed if possible with an allogeneic SCT in CR1 in the 
unfavorable-risk group, not because of the data supporting this, but rather due to the dismal 
outcome with either autologous SCT or following chemotherapy alone. The intermediate-risk 
group representing close to 40% to 50% of all patients with AML has less clearly defined options 
(11). 
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Prognostic factors- 
The treatment outcomes are influenced by various prognostic factors (17-20). Age, cytogenetics, 
Performance scores, comorbidities and socioeconomic status considered prognostic factors (15, 
18, 38-40)(Table A). 
The Swedish Acute Leukaemia Registry , the largest national population based unselected series 
has shown that age  has a strong prognostic impact , regardless of management(41). 
Our current understanding of prognostic factors is summarised in Table A.  
The most important implication of the prognostication is the decision to transplant patients  in  
first complete remission(42).Allogeneic HSCT as a post remission strategy is associated with the 
lowest rates of relapse (43).This benefit is attributable to both the potent graft-versus-leukaemia 
(GVL) effect and the high-dose therapy of standard conditioning regimens(44-49). 
Once a patient has been in remission for 3 years though, the likelihood of relapse declines 
sharply to ≤ 10%(50). 
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Table A- Prognostic factors in AML(51) 
 Standard Intermediate Unfavourable Uncertain 
A. Patient related 
Age  >50 >65 >75  
Performance status  Poor  
Co morbidities  Multiple  
Socioeconomic status White collar  
Race and gender  African American men  
B. Disease related 
WBC count  More than 20/ 30/ 50/ 100,000/μL  
Immunophenotype  CD7/ 11b/ 14/34, HLA-DR  
Cytogenetics (according the 
MRC) 
t(15;17)(q22;q21), 
t(8;21)(q22;q22), 
 
t(16;16)(p13;q22)inv(16)(p
13q22)/  
Regardless of additional 
cytogenetics 
Entities not classified 
as favourable or 
unfavourable 
abn(3q) [excluding t(3;5)(q25;q34)], 
inv(3)(q21q26)/t(3;3)(q21;q26), 
add(5q)/del(5q), -5, 
 t(9;22)(q34;q11), -17, and abn(17p), 
-7,add(7q)/del(7q), 
t(6;11)(q27;q23), 
t(10;11)(p11˜13;q23), other t(11q23) [excluding 
t(9;11)(p21˜22;q23) and t(11;19)(q23;p13)], 
Complex (≥4 unrelated abnormalities) 
Excluding cases with favourable karyotype 
 
Molecular diagnosis: 
CBF AML - t(8;21) + KIT mut inv(16) + KIT mut 
Normal karyotype - FLT3-ITD - 
- NPM1 mut FLT3 wt - TET2 - 
-- CEBPA dm FLT3 wt - DNMT3A NRAS+KRAS 
-  TP53 mut WT1 
-  MDR1 overexposed MLL-PTD 
Secondary AML (in addition 
to karyotype) 
 t-AML in int. 
cytogenetic group 
t-AML in unfavourable group t-AML in favourable 
group 
C. Response related 
Day 14–16 marrow <5% blasts  ≥5% blasts - 
   In a cellular BM - 
PB blast clearance Early - 
MRD Negative  Positive - 
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WT1 (Wilm’s tumour 1 gene) 
 Recurrence is common in the majority of the patients with AML without allogeneic 
transplantation. Leukemia stem cells display resistance to chemotherapy and it may be an 
important reason why it is difficult to eradicate AML cells in the majority of patients. In this 
context; the potential of minimal residual disease (MRD) as a tool to identify response to 
treatment would improve therapeutic strategies.Current methods to evaluate MRD involve the 
follow up of known molecular markers. Patients with persistent elevated levels in fusion 
transcripts at the end of therapy  or associated with transcripts reappearance after molecular 
remission are prone to early relapse(52, 53). Alternative options are based on the detection of 
mutated genes, like FLT3-ITD and NPM1 or over expressed genes, like WT1 (54). 
 WT1 (Wilm’s tumour) was identified originally for its involvement in the pathogenesis of 
Wilm’s tumor and has been shown at high levels of expression in several hematopoietic tumours, 
including AML(55-61). Wilm’s tumor gene WT1 encodes a transcription factor which plays an 
important role in cell growth and differentiation(62, 63).However, the clinical utility 
of WT1 monitoring has been controversial, partly reflecting differences in assay performance to 
date(64-69).It is reported  that  monitoring by real-time quantitative polymerase chain reactions 
(RQ-PCR) to detect leukaemia-specific targets (i.e., fusion gene transcripts such as PML-
RARA or mutations such as that in NPM1) would identify those patients at the highest risk of 
relapse ; thereby providing an opportunity for early treatment intervention (54, 70).There is 
interest in the potential for WT1 assessment to provide a target for sequential MRD monitoring, 
particularly as a tool directed at need for treatment modification, as it is uniformly expressed 
irrespective of cytogenetic and molecular classification.  
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Determining the kinetics of WT1 transcript reduction following induction chemotherapy 
however provides a key prognostic factor, distinguishing patients at differing risk of relapse, 
within cytogenetically defined risk groups.  
The European Leukemia study noted that WT1 transcript reduction post induction might predict 
the relapse risk. The levels of WT1 were assessed after chemotherapy-induced morphologic CR, 
in peripheral blood (PB), and BM in patients with AML. In the multivariate analysis it was noted 
that a ≥ 2-log MRD reduction in WT1 expression was associated with a significantly lower 
cumulative incidence of relapse (P = .004). However only in 13% and46%  of BM and PB 
samples, respectively, were the levels of WT1 sufficiently over expressed, in comparison  to 
normal samples, allowing for a prognostic stratification. Also, as WT1 is expressed in some 
stages of haematopoietic development, but not others, the expression in leukaemia could possibly 
enable to identify  the cell of origin of the malignancy(71, 72). 
Though concerns about the confounding role of the physiologic background of WT1in normal 
PB and BM remain to be addressed, it can be exploited as a potential marker to establish the 
presence, persistence, or reappearance of leukemia (65) . 
INDIAN SCENARIO 
The epidemiology of AML in India is yet to be comprehensively studied; where the results of 
progress made into the biology of the disease as well as in its treatment might not make an 
impact on the majority of the patients. The limited data available on the AML profile in India are 
from single centre experiences(73, 74). 
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With a population of 1200 million the actual cancer burden in our country might account to large 
number of patient cases even though accurate statistics are unavailable. The pattern of 
leukemia’s observed in India as reported in literature is different from what is reported from the 
rest of the world (75-78).The age standardized incidence rates are lower and they occur at an 
earlier age (79).Chronic leukemias are reported as more prevalent amongst adults in India (79, 
80). Among the individual leukemias chronic myeloid leukemia is the most prevalent(76). In the 
first report on the incidence of cancers in 20 population based registries, a male predominance 
amongst leukemias and a higher prevalence in the urban settings is noted(57). 
Despite  the advances and progress in our understanding; we fail  to provide adequate primary 
health care to the majority of our patients(81).  
In a report on health care in India it was recognised that few patients have access to specialized 
treatment(82). A skewed cultural understanding of ill health and well-being, extent of socio-
economic disparities, reach of health services, quality and costs of care and lack of social support 
could amplify the inadequacy in specialised treatment (83-86) . 
There exists a paradox in the Indian health scenario. India has access to highly skilled technical 
communities that can translate ambitious projects into practical reality , however health is rarely 
a decisive political issue and as  a nation our performance is dismal with regards to health 
parameters(87, 88). A few things need to be understood about the Indian public health 
system(89). 
1 There is yet to be developed comprehensive universal health coverage as 
practiced in the west(86, 90). 
2 In our country despite a multitude of public policies only 1.2 % of the GDP is 
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India’s public spending on health(91). 
3 Health schemes implemented by the government fail to reach the under 
privileged(92, 93). 
4 Only 243 million of India’s 1.2 billion citizens are covered under Government 
health insurance schemes and only 10% of our population Indians have some 
form of health insurance with about 40% of Indians having to borrow money or 
sell assets to meet their health care expenses(94-96).  
5 An estimated 55% of the population in India  is poor by the multidimensional 
poverty index(87). 
6 Only 7% children in India receive the minimum acceptable diet set by the 
WHO(44).  
7 Out of pocket expenditure still remains close to 80 % of all spending(8, 97). 
8 India is ranked a low 136 in terms of the human development index (HDI) which 
assesses long term progress in health and social well-being(98). 
9 The annual per capita net national income in real terms is estimated at Rs.39, 
168/-(99). 
It is very imperative to understand this so that appropriate treatment strategies could be planned 
in the context of our health system.  
There have however been no large scale descriptive studies tackling the pattern and patient 
behavior in patients with acute myeloid leukemia which needs to be characterized to improve 
treatment strategies.  
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With costs of primary induction estimated to be around ₹ 4 to 6,00,000/-; it is easy to understand 
that most patients in our country will not afford treatment; and a provision of an efficient, 
affordable and equitable treatment policy for our population will involve much more than the 
quoting and reporting the treatment progress quoted from western literature. 
Identifying pretreatment factors in acute myeloid leukemia is also equally important in 
improving our treatment outcomes. As previously noted in a study from our centre treatment 
outcomes in those who proceed with treatment are similar to those reported in literature. 
Therefore there is a strong need to characterize the disease process and identify factors which 
may provide prognostic information which influence responsiveness to chemotherapy and risk of 
relapse.  
An added objective would be to focus on patient-specific factors, including co morbid conditions 
that may affect an individual’s ability to tolerate chemotherapy. Disease-specific ; individual 
patient and epidemiological factors are to be considered in treatment decisions and undertaking 
improvisations in those might lend to a  significant improvement in outcomes ,considering the 
socio-economic differences and characteristics of the Indian Public health system(100). 
Randomized control studies are lacking in view of lack of investigator or sponsored drive.  
Population based studies may overcome bias in selection and substitute in some situations for 
randomization eventually providing valuable data for the scientific assessment of the many 
problems we struggle with in real world practice(101). 
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Aims and Objectives: 
 
1. Study the  demographic profile of newly diagnosed patients with  acute myeloid leukemia 
at our centre 
 
2. Evaluate treatment and clinical outcome of the above patients treated at our center. 
 
3. Study the role of Wilm’s tumour 1 gene expression as a prognostic and MRD (minimal 
residual disease) marker in acute myeloid leukaemia. 
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Patients and Methods 
This study protocol was approved by our Institutional Review Board (IRB).  
This is a descriptive and prospective analysis of newly diagnosed patients with acute myeloid 
leukemia (AML) diagnosed in the department of hematology at Christian medical college, 
Vellore.  
Duration of the study: 1
st
 of July 2012 till 28
th
 of February 2014. 
Definitions  
Diagnosis- The diagnosis of acute myeloid leukemia was made according to the WHO 
Classification of Tumors of Haematopoietic and Lymphoid Tissues Fourth Edition(5). 
In view of resource constraints the diagnosis of acute myeloid leukaemia was also considered 
on the basis of Auer rods or morphologic examination.  
The presence of ≥ 20% blasts was mandatory either in the peripheral blood or on the bone 
marrow. The presence of < 20 % blasts was acceptable only in those with recurrent genetic 
abnormalities(5).
 
Outcomes- These were based on the ELN recommendation in AML (Table I)(11). 
 
 
 
 
15 
 
(Table I) Definition (11, 102) . 
Category Definition 
Treatment Response 
Complete remission (CR) 
Bone marrow blasts < 5%; absence of extramedullary 
disease; absence of blasts with Auer rods; absolute 
neutrophil count > 1.0 × 10
9/L (1000/μL); platelet count > 
100 × 10
9/L (100 000/μL); independence of red cell 
transfusions 
CR with incomplete recovery 
(CRi) 
All CR criteria except for residual thrombocytopenia (< 
100 × 10
9/L [100 000/μL])or neutropenia (< 1.0 × 109/L 
[1000/μL])  
Treatment failure 
Resistant disease (RD) 
Failure to achieve CR or CRi, only included patients 
surviving ≥ 7 days following completion of initial 
treatment, with evidence of persistent leukemia by blood 
and/or bone marrow examination 
Age group  
Paediatric AML Patients with age≤15 years 
Adult AML Patients between 15-60 years 
Elderly AML Patients ≥60 years 
Cytogenetic Risk Group(Refined MRC Criteria)(19) 
Favourable t(15;17) t(8;21) inv(16)/t(16;16) 
Intermediate Normal; Other non- adverse 
Adverse 
abn(3q) [excluding t(3;5)] inv(3)/t(3;3) add(5q)/del(5q)/ -
5,-7/add(7q) t(6;11) t(10;11) t(9;22) -17abn(17p) with 
other changes Complex (> 3 unrelated abnormalities)  
Excluding those with favorable changes 
Survival outcomes  
Overall survival 
Defined for all patients; measured from the date of 
diagnosis to the date of death from any cause. 
Event-free survival 
Defined for all patients; measured from the date of 
diagnosis to relapse from CR or CRi, or death from any 
cause. 
 Patients whom we could not to contact or establish status were considered dead within 30 
days of their last contact for the purpose of this analysis 
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Patients: 
Inclusion criteria 
All patients diagnosed with acute myeloid leukemia and presenting to the department of 
Clinical haematology at Christian medical college, Vellore were included in the study.  
Exclusion criteria 
Patients diagnosed as AML with recurrent genetic abnormality [t (15; 17); PML-RARA] 
were excluded from this analysis. 
Methods: 
Collection of data: 
After approval by the IRB, all patients diagnosed with AML in Clinical Haematology from July 
2012 till February 2014 were included.  
Demographics- Consecutive patients presenting with the diagnosis of acute myeloid leukemia 
were interviewed. Demographic information and first contact clinical features were recorded at 
interview. Details were recorded in a questionnaire format approved by the institutional review 
board for the study. The demographic data, clinical features and laboratory findings were 
analyzed for identifying the factors associated with acute myeloid leukemia in our cohort of 
patients. 
Clinical information regarding the treatment regimen, post treatment response, induction deaths, 
infective episodes and adverse events were obtained from the hospital records (laboratory 
reports/ physician documentation in hospital charts/hospital discharge summaries). 
 
17 
 
Re-interview: To determine the status of patients who chose not to proceed with treatment, we 
additionally attempted to contact all those patients by telephone. At re-interview; details as to 
type of therapy chosen subsequently, reconfirmation of reason at first contact at our center and 
time till event (if it occurred), was collected. The telephone numbers for contact were obtained 
from the hospital records. 
WT1 assays: Quantitative levels of WT1 were assessed on newly diagnosed acute myeloid 
leukemia patients at diagnosis and in those who received treatment, additionally; at the end of 
induction therapy. However the samples post inductions were limited in view of induction 
deaths, patient refusal and inadequate sampling. Therefore the WT1 analysis is restricted to pre-
treatment diagnosis samples. The paired WT1 samples are planned for analysis at a later date as 
part of an ongoing study once adequate samples are collected. 
Quantitative real-time PCR (RQ-PCR) for WT1 
Bone marrow mononuclear cells (BM-MNC) were isolated using Ficoll-paque (GE Healthcare, 
Foster City, California, USA). Total RNA was extracted from BM-MNCs of AML samples and 
peripheral blood white blood cells (WBC) of normal controls using Tri Reagent (Sigma, USA). 
Complementary DNA (cDNA) synthesis was performed with 1µg RNA using Superscript II 
reverse transcriptase (Invitrogen, Carlsbad, CA, USA) following the manufacturer’s instructions. 
This RQ-PCR assay used the double dye oligonucleotide hydrolysis principle. RQ-PCR assays 
were performed on ABI 7500 fast platform (Applied Biosystems, Foster City, CA). The 
generated cDNA was amplified by PCR using a pair of specific primers and a specific internal 
double dye probe (Fam-Tamra) for WT1 and the control gene ABL. WT1 transcripts were 
normalized to ABL by using the respective plasmid standards to generate normalized copy 
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numbers in addition to the ΔCT method. All assays were run in duplicate wells with appropriate 
non template controls.  
For each patient sample the amount of WT1 and ABL expression was determined from the 
appropriate standard curve generated with each run. WT1 expression, with detectable WT1 copy 
numbers were expressed per 100 ABL copies. 
 
WT1 expression =  Mean copy number of WT1 X 100   
Mean copy number of ABL 
 
 Primer probe sequences for WT1 and ABL.  
WT1 
WT1 Probe: 5’FAM-CAGGATGTGCGACGTGTGCCTGGAG-TAMRA-3’ 
WT1 RQF: 5’-AGAATACACACGCACGGTGTCT-3’ 
WT1 RQR: 5’-GATGCCGACCGTACAAGAGTC-3’ 
 
ABL 
ABL PROBE: 5’FAM-TGCTTCTGATGGCAAGCTCTACGTCTCCT-TAMRA-3’ 
ABL RQF: 5’-GATACGAAGGGAGGGTGTACCA-3’ 
ABL RQR: 5’-CTCGGCCAGGGTGTTGAA-3’ 
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 Data analysis: 
Results were analyzed in terms of the demographic characteristics of newly diagnosed patients 
collected at first contact. The differences in the profile of above collected characteristics were 
compared among the treated cohort and those who did not choose to proceed with treatment. We 
also analysed the characteristics, treatment features, complications and outcomes among those 
who underwent treatment. These results were compared among different age groups as defined 
earlier.  
The cohort of newly diagnosed patients and those who presented at relapse were analysed 
separately. The response to treatment was assessed in terms of Complete Remission (CR/CRi), 
resistant disease and failure/death (Definitions as in table I).  
 All patients started on treatment were followed up for treatment related complications 
including infective episodes and mortality.  
 We calculated a WBC index based on the WBC counts at diagnosis and bone marrow 
blasts using the following formula(103): 
 WBC index= WBC count in 10 9 /L x Blast percentage in bone marrow 
                                                100 
 
 The closing date for analysis was 28th of February 2014.  
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 Statistics: 
 Descriptive statistics were calculated for all variables. Differences in proportions 
were assessed using the χ2 or Fisher exact statistic. Differences in means were tested 
using a Mann-Whitney-U test or t-test as appropriate. The probability of survival we 
estimated with the use of the product-limit method of Kaplan and Meier for overall 
survival and event-free survival and compared by the log-rank test. All survival estimates 
are reported ± 1 SE.  
 The relationships of clinical features to outcome were analyzed by Cox proportional 
hazard model. All P values were 2-sided, with values of .05 or less indicating statistical 
significance. Statistical analysis was performed using SPSS 16.0 software (SPSS, 
Chicago, IL). 
 
 
 
 
 
 
 
 
 
21 
 
RESULTS: 
 A total of 360 patients presented to the department of Clinical Haematology at CMC 
Vellore in a period of 20 months from the 1
st
 of July 2012 till the 28
th
 of February 2014 with 
Acute Myeloid Leukemia. Of these, 318 patients were newly diagnosed and 42 patients had 
presented at relapse (Figure1). 
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RELAPSE (n=42) 
Fig 1: Schematic representation of patients with AML 
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Baseline demographic characteristics in newly diagnosed patients (Table 1 and Figures 1-3) 
 
The majority of our newly diagnosed patients were adults, 224(70.1%) and male, 212 (66.7%). 
The median age at presentation of the cohort of newly diagnosed patients was 40(1-79)years with 
median symptom duration of 4 (1-52) weeks. 
When we analyzed the distribution of patients according to the various age groups we observed 
that the maximum number of newly diagnosed patients were in the 41- 50 age group. There were 
39 patients in the 61-70 and 9 patients in the 71-80age group. 
The cytogenetic data was available in 214 (67.3%) on newly diagnosed patients. Of these we 
noted that the intermediate cytogenetic risk group with 148 (69.2%) and AML not otherwise 
specified, 126(58.9%) were the most common disease related characteristics in our patients. 
Complex cytogenetics with 28 (13.1%) in the adverse risk group and  t (8; 21) in the favourable 
cytogenetic risk group with  20 (9.3%) patients were the commoner types. 
At diagnosis a mean hemoglobin of 77.0 (±23.7) g/L, median white cell count of 14.1 (0.2-
920.0)x 10
9
/L, platelet count of 36.0 (0.2-920.0)x 10
9
/L and a WBC index of 5.6 (0.1-667.8) 
were the laboratory features noted in these patients.  
The median WT1 baseline expression was 13.4 copies/ 10
2
 ABL copies. 
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Table 1: Descriptive baseline demographic characteristics in newly diagnosed patients with AML 
Variable Patients ( N=318) 
n (%)/ Median ( Range)/Mean (±SD) 
Age ( years) 40 (1-79) 
Sex (Male) 212 (66.7) 
Symptom duration ( Weeks) 4 (1-52) 
Distance from CMC (Km) 600 (10 – 3200) 
Treatment at CMC (Yes) 95 (29.9) 
Transplant Status (Yes)** 18 (18.9) 
Performance Score  
      0/1 
      2 
      3/4 
n=311 
247(79.4) 
53(17.0) 
11(3.5) 
Haemogram 
Haemoglobin (g/L) 77.0 (±23.7) 
White blood cell count (x10 9/ L) 14.1 (0.2-920.0) 
Platelet count (x10 9/ L) 36.0 (2.0-364.0) 
Blasts in marrow  
 Blasts in bone marrow (%) 
 White blood cell Index 
n=288 
59.9 (±25.1) 
7.6 (0.1-667.8) 
WT1  
 WT1(copies/102ABL copies) 
n=90 
13.4 (0.01-65.03) 
Cytogenetic Risk  
  Favourable 
  Intermediate 
  Adverse 
n=214 
25 (11.7) 
148 (69.2) 
41 (19.2) 
Favourable risk subtype 
  t(8;21) 
  inv(16);t(16;16) 
25 
20(9.3) 
5 (2.4) 
Adverse Risk  subtype 
  -7 
  del(5q) 
  Complex 
41 
12 (5.6) 
1 (0.5) 
28 (13.1) 
WHO classification  
  With recurrent genetic abnormalities 
  With myelodysplasia related changes 
  Therapy related 
  Not otherwise specified 
  Related to Down syndrome 
n=214 
30(14.0) 
53 (24.8) 
03 (1.4) 
126 (58.9) 
02 (0.9) 
**(% derived from  patients  treated; n=95) 
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We analysed the country and state of origin of all newly diagnosed patients. 295 (93%) patients 
were from India. 21 nationals from Bangladesh and one each from Nepal and Sri Lanka  were the  
patients outside of India who presented to our centre. 
The maximum number of patients from India hailed from Tamil Nadu(35%) followed by those 
from Andhra Pradesh(15%) (Figure 2). 
Housewives , students and retired personscomprised the 165 (51.2%) patients who were 
financially dependent on other members in the family.  
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Figure 1:Patient distribution by age (n) 
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Figure 2:State-wise distribution among newly diagnosed patients (n=295) 
Figure 3: Distribution by financial dependence among newly diagnosed patients N=318 
*Housewives, students and retired person were represented in the economically dependent category        
**Earning members represent the economically independent category       
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Comparison among the treated and untreated patients  
In our analysis of newly diagnosed patients we observed that only 95(29.9%) patients had 
treatment at our centre (Table 1). Considering that the majority of the patients did not proceed 
with treatment, we attempted to analyze the reasons for the same and also to look for any 
differences in terms of demographic characteristics between these two cohorts. 
We first analysed the patient related characteristics, followed by disease related characteristics. 
Subsequently we compared the two cohorts for demographic parameters which were collected at 
interview. 
 
Comparison of demographic characters and clinical features among treated and untreated 
patients (Table 2) 
In our analysis the cohort of patients who did not proceed with treatment were older[ 41(1-79) vs 
38(1-68)years], lived farther[700(10-3200)vs 500(20-3000)km], had a poorer performance 
score[ECOG 2:44(20.4%); 3/4 : 9(4.1%) vs 9(9.5) and 2(2.1)] and were symptomatic for a longer 
period of time[mean 6.8 vs 5.5 weeks; P=0.002] than those who received treatment. 
Feverwas the most common symptom in both the treated and untreated groups. The baseline 
characterisitics are summarized in table 2. 
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Comparison of laboratory parameters among treated and untreated patients (Table 3) 
The untreated cohort was noted to have a lower mean haemoglobin[75.4(±23.6 ) vs 84.4(±22.7 
)g/L;P=0.005] and lower median platelet count [46 (5.0-324.0) vs32 (2.0-364.0) x 10 9 /L]in 
comparison to those who chose to proceed with treatment. 
FLT3 and NPM1 positivity was also noted in a higher proportion of patients who did not proceed 
with treatment. Other features are summarised in table 3. 
 
 
 
Table 2: Baseline demographic characteristics and  clinical features in newly diagnosed patients ( N=318) 
Variable Treated patients (N=95) 
n (%) Median ( Range)/Mean ±SD 
Untreated patients (N=223) 
n (%) Median ( Range)/Mean ±SD 
P 
value 
Age (years) 38 (1- 68) 41 (1-79) 0.040 
Sex (male) 69 (72.6) 143 (64.1) 0.154 
Distance from CMC(km) 500 (20-3000) 700 (10-3200) 0.002 
ECOG Performance Status 
0/1 
2 
3/4 
84 (88.4) 
9 (9.5) 
2 (2.1) 
163 (76.0) 
44 (20.4) 
9 (4.1) 
 
0.034 
Symptom                                                                                                                             n=216 
Symptom duration( weeks) 
Fever (yes) 
Fatigue (yes) 
Bleeding (yes) 
5.5 (±6.8) 
70 (73.7) 
39(41.1) 
20 (21.1) 
6.8(±6.9) 
165 (76.4) 
101 (46.8) 
38 (17.6) 
0.002 
0.668 
0.387 
0.528 
Age groups 
Paediatric AML (≤15) 
Adult AML (15-60) 
Elderly AML (≥60) 
22 (23.2) 
63 (66.3) 
10 (10.5) 
21 (9.4) 
161 (72.2) 
41 (18.4) 
 
0.002 
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Comparison of socio-economic; medical and family characteristics among treated and 
untreated patients (Table 4) 
We observed that those who did not proceed with therapy were represented by a higher 
percentage of tobacco [27(12.6%) vs 3 (3.2%); P=0.011] and alcohol users [18(8.4 %) vs 
2(2.1%); P=0.044] in comparison those who chose to be treated. Similarly there were more 
patients in the untreated cohort with exposure to chemicals [23(10.6%) vs 3(3.2%); P=0.027] in 
comparison to the treated cohort. 
Table3: Baseline Laboratory parameters in newly diagnosed patients ( N=318) 
Variable Treated patients (N=95) 
n (%)/Median ( Range)/Mean ±SD 
Untreated patients (N=223) 
n (%)/Median ( Range)/Mean ±SD 
P 
value 
Haemogram 
Haemoglobin (g/L) 84.4 (±22.7) 75.4 (±23.6) 0.005 
WBC count (x10 9/ L) 12.1 (0.7-742.0) 15.3 (0.2-920.0) 0.925 
Platelet count (x10 9/ L) 46 (5.0-324.0) 32 (2.0-364.0) 0.017 
Bone marrow blasts 
Blasts in bone marrow (%) 
White blood cell Index 
n=93 
64.8(±24.4) 
6.8 (0.3 – 451.2) 
n=196 
 57.5 (±25.2) 
  4.5 (0.1- 667.8) 
 
0.620 
0.132 
Molecular assays 
FLT3/NPM1 
FLT3-/NPM1- 
 FLT3+/NPM1- 
 FLT3-/NPM1+ 
 FLT3+/NPM1+ 
n=83 
61 (73.5) 
3 (3.6) 
7 (8.4) 
12 (14.5) 
                          n=44 
27 (61.4) 
2 (4.5) 
12 (27.3) 
3 (6.8) 
 
 
0.030 
WT1   
WT1 (copies/102ABL copies) 
n=52 
8.8 (0.01-65.03) 
                           n=38 
19.0 (0.04-61.61) 
 
0.075 
Cytogenetic Risk 
Favourable  
Intermediate  
Adverse 
n=94 
12 (12.6) 
62 (65.3) 
20 (21.1) 
                           n=120 
13 (10.9) 
86 (71.4) 
21 (17.6) 
 
 
0.667 
WHO classification 
With recurrent genetic 
abnormalities 
With myelodysplasia related 
changes 
Therapy related 
Not Otherwise specified 
Related to Down syndrome 
n=94 
15 (16.0) 
 
28 (29.7) 
 
3 (3.2) 
47 (50.0) 
1 (1.1) 
                           n=120 
15 (12.5) 
 
25 (20.8) 
 
- 
79 (65.8) 
1 (0.8) 
 
 
 
0.083 
29 
 
The group that proceeded with treatment at our center had a higher representation in ownership 
of vehicles [63(66.3%) vs 60(27.8%); P=0.001], insurance [7(7.4%) vs 4(1.9%); P=0.039] and 
access to financial assistance [18(26.3%) vs 6(2.8%); P=0.001].  
There was no statistical difference in terms of prior therapy with antibiotics [23(24.2%) vs 
47(21.8%); P=0.660], anti-tubercular drugs or food habits [47(49.5%) vs 116(54.0%); P=0.538] 
among the treated and untreated cohort of patients. 
We did not observe any significant statistical difference in the personal and family medical 
history among the two groups (Table 4). 
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Table4: Baseline socio-economic; medical and family characteristics in newly diagnosed patients( N=318) 
Variable Treated patients (N=95) 
n (%)/Median (Range)/Mean ±SD 
Untreated patients (N=211) 
n (%)/Median(Range)/Mean ±SD 
P 
value 
Tobacco (yes) 3(3.2) 27 (12.6) 0.011 
Alcohol (yes) 2 (2.1) 18 (8.4) 0.044 
Exposure to chemicals (yes) 3 (3.2) 23 (10.6) 0.027 
Insurance (yes) 7(7.4) 4 (1.9) 0.039 
Financial assistance (yes) 18 (26.3) 4(2.8) 0.001 
Residence (yes) 92 (96.8) 206 (95.4) 0.185 
Antibiotics (yes) 23 (24.2) 47 (21.8) 0.660 
Anti-tubercular treatment(yes) - 4 (1.9) 0.317 
Prior chemotherapy (yes) 9 (9.5) 14 (6.5) 0.355 
Vehicle (yes) 63 (66.3) 60 (27.8) 0.001 
Air travel (yes) 4 (4.2) 3 (1.4) 0.206 
Use of hair dye (yes) 3 (3.2) 19 (8.8) 0.093 
Married (yes) 42 (44.2) 138 (61.9) 0.004 
Vegetarian (yes) 47 (49.5) 116 (54.0) 0.538 
Order of birth 1 (1-5) 2 (1-5) 0.329 
Family history 
Diabetes (yes) 5(5.6) 16 (8.0) 0.625 
Hypertension (yes) 5(5.6) 10 (5.0) 0.783 
Stroke (yes) - 4 (2.0) 0.314 
Heart Disease (yes)  - 3 (1.5) 0.554 
Cancer (yes) 6 (6.5) 12 (5.7) 0.795 
Medical History 
Diabetes (yes) 13 (13.7) 23 (10.6) 0.446 
Hypertension (yes) 6 (6.3) 24 (11.1) 0.226 
Stroke (yes) 2 (2.1) 2 (0.9) 0.588 
Heart Disease (yes) - 6 (2.8) 0.183 
Other disease# (yes) 19 (20.0) 39 (17.5) 0.999 
Prior malignancy (yes) 6 (6.3) 12 (5.6) 0.795 
# includes recent surgery/thyroid disorders/developmental disorders/marrow failure/seizure 
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Reasons in not proceeding with treatment (Table 5 and 6) 
We observed that inability to afford therapy [174 (81.0%)] and lack of a family member 
[40(18.3%)] to support and stay with the patient for the duration of therapy were the most 
common reasons in declining the choice to proceed with therapy. 
 
 
 
 
 
 
 
 
Table 5: Reason for not proceeding with treatment  
Variable** Patients (N=214) n (%) 
Economic # 174 (81.0) 
Family Support## 40 (18.3) 
Maintain Quality of life 18 (9.5) 
Resignation 11 (5.1) 
Consider Alternative therapy 5 (2.3) 
Communication handicap due to 
language barrier 
4 (1.9) 
Denial of disease 2 (0.9) 
Religious restriction to treat 1 (0.5) 
**More than one reason allowed 
#Inability to meet the costs of therapy represented economic reason ;##Family support was representative of the 
inability to stay with the patient for duration of therapy 
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We attempted to contact all patients who had declined to proceed with treatment by telephone. 
On contact, we re-interviewed the patient/relative regarding the current status of the patient, type 
of treatment taken subsequently and confirmed the reason in not choosing treatment at CMC. 
 123 (55.2%) were contacted (Table 6). At re-interview; 107 patients maintained the same reason 
in not proceeding with therapy.  There were 12 (9.8%) patients who reported being discouraged 
to proceed with therapy as they were counselled regarding the high costs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6:  Reason for not proceeding with treatment on second contact # 
Variable Patients (N=123); n (%) 
Maintain the same reason as at 1
st
 hospital visit 107 (87.0) 
Discouraged/Unhappy with counselling 12 (9.8) 
Other reasons 4 (3.3) 
# 123/223 untreated patients contacted later by telephone 
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Characteristics in those proceeding with treatment (Tables 7-9 and Figures 4-6)  
Patient and disease characteristics (Table 7) 
We noted in our analysis that the majority of those proceeding with treatment were males with a 
good performance score. There were 17(77.3%), 44(69.8) and 8(80.0%) males in the paediatric, 
adult and elderly group respectively. In the ECOG performance of 0/1 category; there were 
20(90.9%), 57(90.5%) and 7(70.0%) patients in the above groups respectively. 
Most of the patients belonged to the intermediate risk based on cytogenetic risk [Paediatric 
14(63.6%), Adult 41(66.1%) and Elderly 8(80.0%)]. Based on the WHO classification of AML; 
across all age groups the most frequent to be treated were the AML not otherwise specified 
[Paediatric 10(45.5%), Adult 30(48.4%) and Elderly 7(70.0%)].  
Other salient features we noted were 
 There were no cases of AML with recurrent genetic abnormality in the elderly group. 
 The mean haemoglobin, median white blood cell and platelet count was not         
statistically different across the groups.  
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Table 7: Patient, disease and treatment characteristics in those proceeding with treatment at CMC 
- Paediatric AML (N=22) 
(≤15) 
Adult AML (N=63) 
(15-60) 
Elderly AML (N=10) 
(≥60) 
- 
Variable n (%)/Median ( Range) 
/Mean ±SD 
n (%)/Median ( Range) 
/Mean ±SD 
n (%)/Median ( Range) 
/Mean ±SD 
P  
value 
Age (years) 12(1-15) 40(17-56) 63.5(60-68) - 
Sex (Male) 17(77.3) 44(69.8) 8 (80.0) 0.684 
ECOG Performance score 
0/1 
2 
3/4 
 
20 (90.9) 
2 (9.1) 
0 (0.0) 
 
57 (90.5) 
4 (6.3) 
2 (3.4) 
 
7 (70.0) 
3 (30.0) 
0 (0.0) 
 
 
0.162 
Cytogenetic Risk Group 
Favourable 
Intermediate 
Adverse 
 
4 (18.2) 
14(63.6) 
4 (18.2) 
 
7 (11.3) 
41 (66.1) 
14  (22.6) 
 
- 
8 (80.0) 
2 (20.0) 
 
 
0.733 
Molecular marker(Intermediate ) 
FLT3+/NPM1- 
FLT3-/NPM1+ 
FLT3+/NPM1+ 
n=13 
2 (15.4) 
2 (15.4) 
- 
n=35 
1 (2.8) 
3 (8.6) 
9 (25.7) 
                n=7 
- 
2 (28.6) 
3 (42.8) 
 
 
0.089 
WHO classification 
With recurrent genetic 
ababnormalities 
With Myelodysplasia related 
chchanges 
Therapy related 
Not Otherwise Specified 
Related to Down syndrome 
 
5(22.7) 
 
4(18.2) 
 
2(9.1) 
10(45.5) 
1(4.5) 
 
10 (16.1) 
 
21 (33.9) 
 
1 (1.6) 
30 (48.4) 
0 (0.0) 
 
- 
 
3 (30.0) 
 
- 
7 (70.0) 
- 
 
 
 
0.238 
Haemogram 
Hb (g/L) 8.5(±2.3) 8.4(±2.3) 8.5(±2.5) 0.992 
WBC count (x10 9/ L) 23 (1.8-742.0) 10.3 (0.7-346.0) 11.9 (1.1-104.2) 0.116 
Platelet count (x10 9/ L) 42.5 (5.0-324.0) 46.0 (6.0-320.0) 53.0(8.0-196.0) 0.949 
Blasts in bone marrow (%) 66.7 (±22.6) 59.3(±25.7) 81.3 (±12.2) 0.090 
White blood cell Index 6.9 (1.1-667.8) 6.9(0.3-268.3) 33.8(0.7-94.8) 0.972 
Molecular markers 
FLT3-/NPM1- 
FLT3+/NPM1- 
FLT3-/NPM1+ 
FLT3+/NPM1+ 
n=18 
14 (77.8) 
2 (11.1) 
2 (11.1) 
0 (0.0) 
n=56 
43 (76.8) 
1 (1.8) 
3 (5.4) 
9 (16.1) 
              n=9 
4 (44.4) 
0 (0.0) 
2 (22.2) 
3 (33.3) 
 
 
0.051 
 
 
WT1 
WT1(copies/102ABL copies) 
n=7 
1.24 (0.01-24.5) 
n=37 
8.2 (0.01-65.3) 
               n=8 
22.5 (2.6-41.1) 
 
0.105 
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Treatment characteristics (Table8; Figure 4 and 5) 
In our analysis of the treatment characteristics, we noted that all paediatric patients [22(100.0%)] 
were treated in our centre with the AML BFM98 protocol as primary therapy for induction 
remission.  The use of hypomethylating agents use was more frequent in the elderly [Decitabine 
4 (40.0%); Azacytidine 2(20.0%)] compared to the adults [Decitabine 5(7.9%); Azacytidine 
1(1.6%)] 
We also analysed the treatment outcomes in the patients treated. Induction deaths were noted in 
5(22.7%), 15(23.8%) and 2(2.0.0%) patients in the paediatric, adult and elderly group 
respectively; P=0.777.  It was observed that CR/CRi was achieved in 13(59.1%), 37(58.7%) and 
1(10.0%) patient in the paediatric, adult and elderly group respectively; P=0.005. 
In order to estimate the incidence of infections, we analysed the blood cultures in all treated 
patients sent during admission for remission induction chemotherapy. We noted that in 
41(43.0%) patients, blood cultures during febrile episodes were sterile. We also observed that the 
most common organism in the blood cultures with isolates were [GNB] gram negative bacilli 
[37(39%)].Carbapenem resistance was noted as a feature in 17(46%) of the GNB isolated. 
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Table 8: Treatment features in newly diagnosed patients (n=95) 
- Paediatric AML(N=22) 
(≤15) 
Adult AML (N=63) 
(15-60) 
Elderly AML (N=10) 
(≥60) 
- 
Variable n (%)/Median( Range) 
/Mean ±SD 
n (%)/Median ( Range) 
/Mean ±SD 
n (%)/Median ( Range) 
/Mean ±SD 
P value 
Treatment Regimens* 
AML BFM 98 22(100.0) - -  
 
 
 
- 
7/3 - 53(84.1) 4(40.0) 
5/2 - 3(4.8) - 
Decitabine - 5(7.9) 4(40.0) 
Azacytidine - 1(1.6) 2(20.0) 
HiDAC - 1(1.6) - 
Bone Marrow Transplant (consolidation) 3 (13.6) 14 (22.2) 1 (10.0) 0.505 
Treatment Responses 
Induction deaths 5 (22.7) 15 (23.8) 2 (20.0) 0.777 
CR/CRi 13 (59.1) 37 (58.7) 1 (10) 0.005 
Resistant disease 5 (22.7) 13 (20.6) 5 (50.0) 0.005 
Infections – During Induction Chemotherapy 
Negative blood cultures 9 (40.9) 26 (41.3) 6 (60.0) 0.691 
Gram Negative Bacilli 10(45.5) 25 (39.7) 2 (20.0) 
Carbapenem  Resistant  organism 1 (4.6) 14 (20.6) 2(20.0) 0.205 
Fungus 8 (36.4) 28 (44.4) 5 (50.0) 0.723 
* 7/3 – Idarubicin12 or daunorubicin 60mg/m2( 3 days) with cytosine 200mg/m2 as continuous infusion(7 days) 
   5/2- Daunorubicin 60mg/m2( 2 days) with cytosine 200mg/m2 as continuous infusion(5 days) 
   HiDAC-High Dose(3g/m2) cytosine (q 12 h for 3 days) 
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Figure:4 Incidence of Fungal infections during  induction chemotherapy 
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Figure :50 Bacterial Blood Culture Isolates during induction in treated newly diagnosed patients  
( N=95) 
CRO- carbapenem resistant organism 
GNB- Gram negative bacilli 
GPC- Gram positive cocci 
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Causes of induction deaths (Table 9 and figure 6) 
 
In our analysis of the treatment outcomes we had noted that 22(23.2%) patients had died 
induction. In a further analysis of the causes of death in those who died, we observed that all the 
22patients (100.0%) had experienced febrile neutropenia. We also observed that in 14(60.9%) 
patients, there was a clinical focus of infection of which the most common clinical focus was a 
sino-pulmonary infection seen in 8(57.2%) patients. We noted that an associated abdominal pain 
was identified in 10 (43.5%) patients who died.  
Considering the incidence of neutropenia, we attempted to analyze the incidence of fungal 
infections. We categorized the fungal infections by the EORTC (European Organization for 
research and treatment in cancer) criteria as follows (104): 
a. Proven IFD: Requiring proof of IFD in diseased tissue for most conditions by 
demonstration of fungal elements  
b. Probable IFD: Require that a host factor, clinical features, and mycological evidence be 
present 
c. Possible IFD: Includes only those cases with the appropriate host factors and with 
sufficient clinical evidence consistent with IFD but for which there was no mycological 
support 
In our analysis of induction deaths, invasive fungal disease (IFD) based on EORTC criteria 
of proven possible or probable was present in 12(52.2%) of patients. Additionally gram 
negative bacilli (GNB) was the most common organism isolated in patients who expired and 
10(71%) were Carbapenem resistant. 
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Figure :6 Bacterial Blood Culture Isolates in Induction Deaths 
( N=22) 
CRO- carbapenem resistant organism 
GNB- Gram negative bacilli 
GPC- Gram positive cocci 
Table 9:Causes and features in induction death (n=22) 
Variable Patient n (%) 
Febrile Neutropenia 22 (100.0) 
Clinical focus of infection (CFI) 
Sino-pulmonary 
Gastro-Intestinal 
Hepatic 
Skin/soft tissue 
14(60.9) 
8 (57.2) 
3 (21.4) 
2 (14.3) 
1 (7.1) 
Abdominal pain 10 (43.5) 
Invasive fungal disease (EORTC*)-IFD 
Proven IFD 
Probable IFD 
Possible IFD 
12(52.2) 
1(8.4) 
8(66.6) 
3(25.0) 
Bacterial infection in blood culture 
 Carbapenem  Resistant  organism 
   Others 
17(77.0) 
10(58.8) 
7(41.2) 
*EORTC- European  Organization for Research and Treatment in cancer definitions for IFD 
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Comparison of characteristics in newly diagnosed and relapsed patients (Table 10) 
We had noted that there were also 42(11.6%) patients who had presented with a disease relapse 
along with the 318(87.4%) who were newly diagnosed. 
 We compared the demographic characteristics between the two groups at presentation. In our 
analysis, the median age of relapsed patients, 38(1-79) was lower than newly diagnosed patients, 
40(1-79) years; P=0.022. We observed that 125(58.7%) and 20(64.5%) patients in the newly 
diagnosed and relapsed cohort had AML not otherwise specified. It was also noted that the 
intermediate cytogenetic risk group was represented by 147(69.0%) and 22(52.4%) patients in 
the newly diagnosed and relapsed cohort respectively; P=0.911.  
Analysis of laboratory parameters revealed mean haemoglobin in the relapsed cohort was 
102.0(±2.9) g/L compared to 77.0(±2.4) g/L in the newly diagnosed; P=0.000. 
The other features in comparison are summarized in table 10. 
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Table 10: Comparison of baseline characteristics among relapsed and newly diagnosed patients with AML 
Variable Newly Diagnosed(N=318) 
n (% of available data)/  
Median ( Range)/Mean (±SD) 
Relapsed ( N=42) 
n (% of available data)/ 
 Median ( Range)/Mean (±SD) 
P 
value 
Age ( Years) 40 (1-79) 38 (1-79) 0.022 
Distance (Km) 600 (10-3200) 715 (70 – 2400) 0.216 
Sex (Male) 212 (66.7) 28 (66.7) 1.00 
Age group 
  Paediatric AML (<15y) 
  Adult AML (15-60y) 
  Elderly AML  (>60y) 
 
43 (13.5) 
224 (70.4) 
51 (16.0) 
 
6 (14.3) 
35 (83.3) 
1 (2.4) 
 
 
0.096 
Treatment at CMC (Yes) 
Transplant Status (Yes) 
95 (29.8) 
18 (5.6) 
25(59.5) 
9(21.4) 
0.000 
0.002 
Cytogenetic Risk  
Favourable  
Intermediate  
Adverse 
n=213 
25 (11.7) 
147 (69.0) 
41 (19.2) 
n=31 
4 (9.5) 
22 (52.4) 
5 (11.5) 
 
 
0.911 
WHO classification 
With recurrent genetic 
aabnormalities 
With Myelodysplasia related 
cchanges 
Therapy related 
Not Otherwise specified 
Related to Down syndrome 
n=213 
30 (14.1) 
 
53 (24.9) 
 
3 (1.4) 
125 (58.7) 
2 (0.9) 
n=31 
6(19.4) 
 
5(16.1) 
 
- 
20 (64.5) 
- 
 
 
 
0.687 
Haemogram 
Hb (g/L) 
WBC count (x109/ L) 
Platelet count (x109 / L) 
n=318 
77.0 (±24) 
14.1 (0.2-920.0) 
36 (2.0-364.0) 
n=40 
102.0(±29) 
6.2 (0.3-241.2) 
74.5 (1.0-541.0) 
 
<0.001 
0.018 
0.004 
Bone marrow blasts 
Blasts in bone marrow (%) 
White blood cell Index 
n=288 
59.9(±25.1) 
5.6 (0.1-667.8) 
n=38 
61.6 (±24.3) 
5.0 (0.3-140.4) 
 
0.854 
0.719 
WT1 
WT1(copies/102ABL copies) 
n=90 
13.4 (0.01-65.0) 
n=16 
34.8 (0.86-98.1) 
 
0.019 
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WT1 expression (Tables 1; 3; 7 and10) 
In our analysis of WT1 expression; we observed that the median baseline WT1 expression at 
presentation was 13.4(0.01-65.03) copies/ 10 
2 
ABL copies. We also noted that the WT1 
expression at baseline was higher in those who did not proceed with treatment compared to the 
treated [19.0(0.04-61.61) vs 8.8(0.01-65.03) copies/ 10 
2 
ABL copies].It was observed that across 
age groups; the expression increased as the group became older. However this was not 
statistically significant. The expression levels were1.24 vs 8.2 vs 22.5 copies/ 10 
2 
ABL copies; 
P=0.105 in the paediatric, adult and elderly age group respectively (Figure 7). We also observed 
that the expression is higher among patients who present at relapse [34.8 (0.86-98.1)] in 
comparison to the newly diagnosed patients [13.4 (0.01-65.0) copies/ 10 
2 
ABL copies] 
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Figure 7: WT1 baseline distribution across age groups 
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Survival statistics (Figures 8-12) 
We analysed the survival of all newly diagnosed patients together and by categorizing them into 
cytogenetic risk groups and the age groups using the Kaplan –Meier estimates. 
OS in newly diagnosed patients (Figure 8) 
At the time of analysis the overall survival of the entire cohort including the treated and those not 
treated was 20.8% ± 2.8% at 12 months with a median follow up of one month.  Patients who 
were lost to follow up beyond a period of 30 days were categorized as dead for the purpose of 
this analysis. 
OS and EFS in newly diagnosed patients by treatment decision (Figure 9a and 9b) 
A log rank comparison among treated and untreated showed a statistically significant survival 
advantage. With a median follow up period of 3months and 1 month for the treated and those 
that did not proceed with treatment; the one year overall survival was 58.7% ± 6.0%  and 7.9% ± 
2.1% respectively.  (P value=0.000) 
The Event free survival for the same group at one year with a median follow up period of 
3months and 1month was 42.7% ± 7.0% and1.3% ± 1.3% respectively.  (P value=0.000) 
OS and EFS in newly diagnosed patients according to cytogenetic risk (Figure 10a and 10b) 
A further analysis of new patients along the cytogenetic risk categories highlighted an improved 
Overall survival and Event-free survival for the favourable cytogenetics group. With a median 
follow up period of 5, 3 and 2 months; the one year overall survival for the Favourable, 
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Intermediate and Adverse risk groups were, 85.7% ± 13.2% ;56.1% ± 7.5% and 47.7%± 13.1%  
respectively. 
The One year Event-free survival for the Favourable, Intermediate and Adverse risk groups 
were, 85.7% ± 13.2% ;38.2% ± 8.6% and 30.7%± 13.1%  respectively with a median follow up 
period of 5, 3 and 2 months. 
There was no statistical superiority in the overall survival (P value=0.097); however the event 
free survival was superior. There was a significant survival advantage for the favourable risk 
group over other groups and the intermediate risk group over adverse risk group, (P= 0.041). 
OS and EFS in newly diagnosed patients according to age group (Figure11a and 11b) 
With a median follow up period of 4, 3 and 2.5 months the One year overall survival for the 
paediatric, adult and elderly age groups were, 72.1% ± 9.7% ;57.3% ± 7.6% and 52.5% ± 18.6% 
respectively.(P value=0.806) 
The One year Event-free survival for the paediatric, adult and elderly age groups were, 45.4% ± 
14.2% ;44.5% ± 8.5% and 26.3%± 20.8%  respectively with a median follow up period of 4, 3 
and 2.5 months;.(P value=0.759) 
OS in patients presenting at relapse with AML (Figure 12) 
When we analyzed survival among those who were treated and those that did not proceed with 
treatment; the one year overall survival in the treated was 42.7% (± 12.1%) and 10 month overall 
survival in those who did not proceed with treatment was 13.7% (± 0.9%) ;at a median follow up 
period of 9and 1month respectively; (P value=0.005) 
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Survival curves in figures 
 
 
 
 
 
 
 
 
 
Figure 8: Kaplan Meier curve for overall survival in newly diagnosed patients with AML (n=318).  
 The One year OS was 20.8% ± 2.8% at a median follow up of 1 month. 
Figure 9a: Kaplan Meier curve for OS of newly diagnosed patients by treatment decision.                 
With a median follow up period of 3months and 1 month for the treated and those that did not proceed with treatment; 
the one year overall survival was 58.7% ± 6.0%  and 7.9% ± 2.1% respectively.  (P value=0.000) 
 
Figure 8 
Figure 9a Figure 9b 
Figure 9b: Kaplan Meier curve for EFS of newly diagnosed patients by treatment decision.             
With a median follow up period of 3months and 1 month for the treated and those that did not proceed with treatment; 
the overall survival was 42.7% ± 7.0% and 1.3% ± 1.3% respectively. (P value=0.000) 
 
Treatment in CMC n=25  
58.7% ±6.0% 
 
Did not proceed with treatment in CMC n=17                                     
7.9% ±2.1% 
 
Treatment in CMC n=25 42.7% 
±7.0% 
 
Did not proceed with treatment in CMC n=17                       
1.3% ±1.3% 
 
 
P=0.000 
 
P=0.000 
 
     n=318                           
20.8% ± 2.8% 
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Figure 11a: Kaplan Meier curve for OS in treated newly diagnosed patients according to the Age group.           
With a median follow up period of 4, 3 and 2.5 months the One year overall survival for the paediatric, adult and elderly age 
groups were, 72.1% ± 9.7% ;57.3% ± 7.6% and 52.5%± 18.6% respectively.(P value=0.806) 
Figure 11b: Kaplan Meier curve for EFS in treated newly diagnosed patients according to Age group.             
With a median follow up period of 4, 3 and 2.5 months ; the One year Event-free survival for the paediatric, adult and elderly age 
groups were, 45.4% ± 14.2% ;44.5% ± 8.5% and 26.3%± 20.8%  respectively.(P value=0.759) 
Figure 10a: Kaplan Meier curve for OS in treated newly diagnosed patients according to the cytogenetic risk.                   
With a median follow up period of 5, 3 and 2 months; the one year overall survival for the Favourable, Intermediate and Adverse 
risk groups were, 85.7% ± 13.2% ;56.1% ± 7.5% and 47.7%± 13.1%  respectively.(P value=0.097) 
Figure 10b: Kaplan Meier curve for EFS in treated newly diagnosed patients according to the cytogenetic risk. With a 
median follow up period of 5, 3 and 2 months; the One year Event-free survival for the Favourable, Intermediate and Adverse risk 
groups were, 85.7% ± 13.2% ;38.2% ± 8.6% and 30.7%± 13.1%  respectively. There was a significant survival advantage for the 
favourable risk group over other groups and the intermediate risk group over adverse risk group (P value=0.041). 
 
 Figure 11a Figure 11b 
Figure 10a Figure 10b 
Favourable n=12                     
85.7%±13.2%          
Intermediate n=62                     
38.2% ±8.6%          
Adverse n=20                    
30.7%±13.1%          
P=0.041 
Favourable n=12                     
85.7%±13.2%          
Intermediate n=62                     
56.1% ±7.5%          
Adverse n=20                    
47.7%±13.1%          P=0.097 
Paediatric n=22                         
72.1%±9.7%          
Adult n=63    
57.3%±7.6%          
Elderly n=10    
52.5%±18.6%          
P=0.806          
Paediatric n=22                         
45.4%±14.2%          
Elderly n=10    
26.3%±20.8%          
Adult n=63    
44.5%±14.2%          
P=0.759          
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Figure 12: Kaplan Meier curve for OS stratified by treatment decision in patients presenting at relapse.        
The overall survival in the treated and those who did not proceed with treatment were 42.7% ± 12.1%at one year 
and 13.7% ± 0.9% at 10 months ;at a median follow up period of 9and 1month respectively; P value=0.005 
 
 
 
 
 
 
 
 
 
 
Figure 12 
Treatment in CMC n=25 
42.7% ± 12.1% 
 
Did not proceed with treatment in CMC n=17  
 13.7% ± 0.9% 
 
P = 0.005 
48 
 
Discussion 
Acute myeloid leukemia is described as a disease of the elderly with a median age reported from 
69 to 72 years (38, 105). Outcomes are cited to be improving, more to the advances in supportive 
care than to any therapeutic break-through(106). The patterns of haematological malignancies 
may reveal geographical differences which need to be accurately studied to enable a better 
understanding (107, 108).There is however, a lack of data on the demographic profile and 
clinical outcomes in patients with Acute myeloid leukemia from India. 
Demographic data  
The median age of incidence in AML observed in our study is 40(1-79) years. This is earlier by 
three decades, what is reported in literature based on registries from Europe and America (14, 
109).On the basis of age and incidence rates, it is postulated that there are cumulative 
pathogenetic events in AML whereas the flat incidence rates in ALL and APML, lends support 
to fewer pathogenetic events (38).Our observation is similar to other reports from Asia where the 
median age is reported lower than the western population (110-112).This might suggest 
alternative disease biology in our patients.   A male preponderance of 224(66.7%) patients is 
noted in our study. This is comparable to the male excess in AML reported in literature (38, 
113). A greater exposure to carcinogenic events is a postulation (114). Additionally ;gender 
related health care distance propagated by the chronic neglect of  women in India; might amplify 
this gender disparity(85, 115). 
The inadequacy of medical infrastructure in India has been frequently reported(85). It is noted in 
the case of other medical interventions that distance to health care facilities is a significant 
barrier to availing treatment(116).The median symptom duration of 4 (1-52) weeks and distance 
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travelled of 600(10-3200) km is possibly a reflection of the same. Our patients hailed from Tamil 
Nadu to as distant as Tripura. Many of our patients were from the East and North-East India who 
have limited health care access(117). Treatment areas being distant; patients develop a tendency 
to postpone their assessment for a later date(85, 118).  
Laboratory and disease related features in newly diagnosed patients. 
The mean haemoglobin of 77.0(±23.7) g/L; white blood cell count of 14.1 (0.2-920.0) x 10 
9 
/L; 
and the platelet count of 39.0 x 10
9
 /L at presentation in our analysis, is lower than reports from 
other countries (14, 112). We postulate that this could be due to the national tendency to delay 
the decision to seek appropriate care(119, 120). The intermediate cytogenetic risk group with 
148 (69.2%) and AML not otherwise specified with 126 (58.9%) patients were the most frequent 
disease characteristics noted. This is consistent with observations from other centers (111, 121, 
122) . However in comparison to reports categorizing AML by the WHO classification we 
observed a lower number of patients[ 25(11.7%)] with recurrent cytogenetic risk(123).This we 
postulate to the  study design to exclude patients with t ( 15;17). 
Differences among patients who proceed with therapy and those who decline treatment. 
Differences in demographics 
A total of 95 (29.8%) patients decided to proceed with treatment at our center, This is strikingly 
lower than that reported from western countries where the access to free government sponsored 
health care is higher(124).In our analysis we noted that that those who declined therapy were 
older(41 vs 38 years ;P=0.040) and travelled from farther ( 700 vs 500 km;P=0.002). The young 
and those with lower performance scores were better represented in the treated group 
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(P=0.034).There is no such criteria in our hospital’s decision to treat patients, and the above 
selection bias might be reflective of the informed decision process. 
We also observed that those who did not proceed with therapy were represented by a higher 
percentage of tobacco [27(12.6%) vs. 3 (3.2%); P=0.011] and alcohol users [18(8.4 %) vs 
2(2.1%); P=0.044].This could reflect a possibility that those who did not proceed with treatment 
represented the poorer sections of our society(125).Reflective of the better economic standing in 
patients who choose to proceed with therapy; we observed that this group had a higher 
ownership of vehicles [63(66.3%) vs 60(27.8%);P=0.001], insurance [7(7.4%) vs 4(1.9%); 
P=0.039] and financial assistance [18(26.3%) vs 6(2.8%); P=0.001]. We did not observe any 
significant statistical difference in the personal and family medical history among the two groups 
(Table 4). 
Laboratory and disease related differences in newly diagnosed patients. 
The lower mean haemoglobin of 75.4(±23.6) vs 84.4 (±22.7) g/L;P=0.005, platelet count of 32.0 
(2.0-364.0) vs 46 (5.0-324.0) x 10
9
 /L; P=0.017, might be reflective of an advanced disease 
presentation in the cohort who did not proceed with treatment. There were no significant 
differences in the disease risk or WHO classification among the two groups. 
Decision patterns in declining therapy. 
Decision behavior is influenced by various factors(126) .We observed that inability to afford 
therapy[ 174 (81.0%)] and lack of a family member [40(18.3%)]to support and stay with the 
patient for the duration of therapy were the most common reasons in declining the choice to 
proceed with therapy. Other reasons which we observed in our study are noted in table 5. The 
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need to a maintain a similar quality in life as a reason for deferring therapy has been noted with 
other diseases(127). 
On re-interview we observed that 16(13.0%) patients attributed a different reason to the one they 
administered at first visit. The commonest explanation being counselling driven; is a possible 
reflection of the health care approach in India(128). 
Characteristics of patients who underwent treatment: 
We did not observe any statistically significant differences across the various age groups in 
relation to patient and disease characteristics. The Elderly cohort had a higher representation of 
patients with poorer performance scores, higher platelet count and WBC Index. (P<0.05) 
In our analysis there was no patient in the Elderly cohort with favourable cytogenetics. This is in 
contrast to observations from other registries where the incidence of favourable cytogenetics is 
constant with age(129). Our findings are similar to recent data from the Swedish registry where 
the incidence of the favourable karyotype decreased with age (130). Our observations with mean 
haemoglobin, white blood  cell and platelet count are lower than those reported from the SWOG 
trial data, however the marrow blast percentage was similar to their observations(14).Across age 
groups; it was observed that the WT1 expression increased as the group became older. The 
expression levels were1.24, 8.2 and 22.5copies/10 
2
 ABL copies (P=0.105) in the paediatric, 
adult and elderly respectively. 
Treatment features:                                                                                                                        
The conventional 7+3 regime is the most commonly used therapeutic protocol in induction in 
Adults and the Paediatric AML BFM 98 in patients’ ≤ 15 years at our centre. The Elderly group 
had a higher representation of patients on hypomethylating agents.  
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There were 13(59.1%), 37(58.7%) and 2 (20%) patients who attained CR following first cycle of 
induction in the paediatric, adult and elderly groups respectively. Those who had a resistant 
disease, defined as those who failed to enter CR after the first course of induction chemotherapy 
were 5(22.7%), 13(20.6%) and 5(50%) respectively in the paediatric, adult and elderly groups. 
These results are lower than those reported from the SWOG trial dataset with 60% and 31% 
respectively(14). Similar treatment outcomes have been reported from the university hospital 
,Brazil (131).In our analysis the induction death occurred in 5(22.7%), 15(23.8 %) and 2(20.0%) 
across the age groups. A recent analysis of patients enrolled in trials at the SWOG  and MDACC 
receiving intensive therapies from 1991-2009 reported a sharp decline in treatment related 
mortality(3%-4%) from 2006-2009(106). The higher rate of bacteremia and infection with 
fungus and multidrug resistant strains in our analyses might be possible reasons for such striking 
differences in observation. We also recognize that unlike above reports, our study is not in the 
setting of a clinical trial. We noted 56(57%) patients to be bacteremic .Gram Negative Bacilli 
were the predominant isolate in them and of these 17(46%) were carbapenem resistant 
organisms. Such high rate of carbapenem resistance is a cause for worry. Another major concern 
along with bacterial infections is the changing trends in fungal disease in developing 
countries(132).We also noted that Invasive fungal disease was associated with 12 (52.2%) of the 
induction deaths. This is comparable to attributable mortality rates reported from an earlier study 
by Pagano et al(133). Our observations on infections are strikingly higher than what is reported 
from other centers.  
The Japanese Acute Leukemia Group identified bacteremia in 9.5% cases with gram positive 
cocci (49%)as their major isolate(134).The higher incidence of gram positive organisms was also 
noted by the Polish Acute Leukemia Group(135). The incidence of carbapenem resistant 
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organism by the European group for blood and marrow transplantation of 5-14% is also 
contrastingly lower (136) .However our resistant rates are comparable to reports from other 
centers in India where a prevalence of 40-50% in enterobacteriace has been noted(137). 
WT1: Role in prognosis 
We observed that the median baseline WT1 expression at presentation was 13.4(0.01-65.03) 
copies/ 10 
2 
ABL copies. This is lower than reports from European Leukemia net and Italy where 
the median values obtained were 25.5 and 93.6copies/ 10 
2 
ABL copies respectively(65, 
138).Across age groups; it was observed that the expression increased as the group became older. 
However this was not statistically significant. The expression levels were1.24 vs 8.2 vs 22.5 
copies/ 10 
2 
ABL copies; (P=0.105) in the paediatric, adult and elderly age group respectively. 
The WT1 expression at baseline was higher in those who did not proceed with treatment. The 
WT1 expression though not statistically significant (P=0.075) was noted to be higher in the 
cohort which did not receive treatment at CMC (19.0 vs 8.8 copies/10 
2
 ABL copies).  
We also noted that it was higher in those who presented at relapse [34.8 (0.86-98.1)copies/ 10 
2 
ABL copies] compared to the newly diagnosed. This is a statistically significant observation; 
(P=0.019). Higher WT1 expression might relate to a higher disease burden (138, 139). 
In order to derive the role in our subset of patients more numbers and paired assays at different 
time points in treatment are required. 
Comparison among patients who present at relapse and newly diagnosed patients. 
This comparison revealed that; at relapse, patients presented with a higher haemoglobin (10.32 
vs 7.8) and platelet count (74.5 vs 36.0 x 10 
9
/L). There are no biological explanations to this 
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observation. This might relate to a self-selection bias in this group of patients who at relapse seek 
medical attention earlier(140).There was no difference in the cytogenetic or WHO classification 
based disease characteristic. 
Survival statistics 
We analysed our survival data on the basis of treatment decision, cytogenetic risk and age group. 
The overall survival of 20.8 %( ±2.8%) might be reflective of the study design where patients not 
contactable were considered dead. Our survival in newly diagnosed patients is lower than 
survival reported in the AML 96 and a polish trial evaluating cladribine in AML (141, 142) . The 
survival is comparable to CALGB report of median survival of 1.2 months (20).  
We noted a significant advantage in event free survival for the favourable cytogenetic risk group 
over the others (P=0.000). The Elderly and those with adverse cytogenetics had the least EFS 
and OS among those treated. (Figures 7-14) 
These observations are consistent with survival patterns reported across registries and other 
centers (11, 20, 143).In the analysis of patients who received treatment at relapse we noted a 
median OS of 9 months and a one year OS of 42.7 %( ±12.1%). These are higher than what is 
reported in literature; however this needs to be interpreted in consideration with the short 
duration of follow up. Rowe and colleagues had reported a 5 year OS of 11% based on the 
ECOG data(144). 
Various demographic observations reported in literature have been tabulated for comparison 
(Table II). 
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Table II: Comparison of demographic features in patients with AML reported in literature 
 
Study center/ 
country 
 
Period 
 
N 
 
Age 
(y) 
 
Blast 
(%) 
 
Hb 
(g/L) 
 
TLC 
(109/L) 
 
Platelet 
(109/L) 
 
Adverse 
Karyotype 
 
ECOG 
0/1(%) 
 
Induction 
death (%) 
 
CR 
(%) 
SWOG(14) 
USA 
1990-1996 968 - 70* 92* 19* 49* 33* 77 12 50 
MDA(106) 
USA 
1991-2009 470 56 - - 05 45 - 86 4 - 
SWOG(106) 
USA 
1991-2009 498 49 - - 13 55 - 87 3 - 
FHCRC(145) 
USA 
2008-2011 116 57 - - - - 20 87 - 68 
MRC12(146) 
UK 
1994-2002 2934 41 - - 14 - 15 88 - 85 
Sweden(38) 
SWEDEN 
1997-2005 2767 72 - - - - 23 53 10 65 
JALSG(111) 
JAPAN 
1997-2001 638 45 - 83 14 52 8 - - - 
AKU(147) 
PAKISTAN 
1988-1996 74 38 - 83 49 65 - 65 29 - 
Haryana 
INDIA(148) 
2008-2012 220 28  85 44 67 - - - - 
TMH(74) 
INDIA 
1998-2000 260 27 57 68 - 63 - - - - 
CMC** 
INDIA 
2012-2014 318 40 60 77 14 36 19 79 23 53 
SWOG, South West Oncology Group; MDA, MD Anderson Cancer centre; FHCRC, Fred Hutchinson Cancer Research Centre; 
JALSG. Japanese Acute Leukemia Study Group; AKU, Aga Khan University; TMH, Tata Medical Hospital;  
CMC, Christian Medical College ;*only inclusive of patients <56 years;**Present Study 
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Limitations of the study 
 
We report on potential limitations that could affect the interpretation of our results. 
 This study and its conclusions are based on the data derived from a single tertiary care institute 
and could lead to clustering of cases, not representative of the entire population. Also, conclusion 
on treatment features and outcomes is limited by the small proportion of patients proceeding with 
treatment and the limited follow up. We also recognize that there are multiple overlapping 
questions and reasons (for not proceeding with treatment in the questionnaire). A narrowing of 
different reasons into fewer themes; would enable better understanding of the decision behavior 
in our patients. Also, recruiting information at times of patient crises lends to compromise in 
objectivity of some answers. We recognize that the small numbers and absence of paired post 
induction samples limit the interpretation of our WT1 results. 
A prospective study which is multi-centric, with larger numbers, more objective questioning, 
pairing of post therapy samples with the diagnostic marrow samples and longer duration of 
follow up could be ideal in deriving the demographic and clinical outcome of our patients.  
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Conclusions 
The median age of patients with AML in India noted in our study is three decades earlier than 
that reported in the literature. We noted that less than one third of our patients proceed to 
treatment after diagnosis. In comparison to those who are treated, patients who do not proceed 
with treatment have more adverse clinical, disease and laboratory features. Importantly, the 
inability to finance treatment costs and inability to accompany the patient for the duration of 
therapy were the main reasons in declining therapy identified in our study. 
In our analysis of treatment related features, 7+3 regime is the most commonly used therapeutic 
protocol in induction in Adults and the Paediatric AML BFM 98 in patients’ ≤ 15 years at our 
centre. We also observed that age group and cytogenetic risk are predictive of treatment 
outcomes in our population. A major concern is the incidence of infections both bacterial and 
fungal, higher than reported in literature. We also report on induction death which is higher than 
that cited in literature with invasive fungal disease being present in greater than 50% of 
individuals who died during induction. 
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